Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. [electronic resource]
Producer: 20130424Description: 599-607 p. digitalISSN:- 1529-0131
- Abatacept
- Antigen-Presenting Cells -- drug effects
- Antirheumatic Agents -- therapeutic use
- Arthritis, Rheumatoid -- drug therapy
- B7-1 Antigen -- metabolism
- B7-2 Antigen -- metabolism
- Cell Adhesion Molecules -- metabolism
- Cell Movement -- drug effects
- Female
- Human Umbilical Vein Endothelial Cells
- Humans
- Immunoconjugates -- therapeutic use
- Lipopolysaccharide Receptors -- metabolism
- Male
- Middle Aged
- Monocytes -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.